Conference Proceedings

A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: Final results of the ZoMaxx II trial

William A Gray, Alan C Yeung, Donald E Cutlip, Jeffrey J Popma, Peter J Fitzgerald, David O Williams, Hubertus Heuer, Charles D O'Shaughnessy, Paul A Overlie, J Tift Mann, Louis A Cannon, James B Hermiller, Timothy D Henry, Robert Whitbourn, Thomas D Stuckey, Mark G Midei, Jessie Coe, Lewis B Schwartz

INTERNATIONAL JOURNAL OF CARDIOLOGY | ELSEVIER IRELAND LTD | Published : 2012

Abstract

BACKGROUND/OBJECTIVES: The purpose of this prospective, randomized, single-blind controlled clinical trial was to compare the effectiveness of a zotarolimus-eluting stent (ZoMaxx™) with a paclitaxel-eluting coronary stent (Taxus™ Express(2)™) in patients with angina pectoris and a single native coronary artery lesion between 10-28 mm in length and 2.5-3.75mm in diameter. METHODS: Patients were enrolled at 75 international institutions between June 2005 and November 2006. RESULTS: 1099 (1672 originally planned) patients received 557 ZoMaxx and 542 Taxus stents: cohorts were well-matched for diabetes (27% vs. 27%), reference vessel diameter (2.73 ± 0.46mm vs. 2.74 ± 0.45mm) and lesion length (..

View full abstract